Bioliberty Raises €2.95 Million in Series A Extension
Edinburgh and Boston-based rehabilitation technology company adds four institutional backers to its funding round.
Updated on Nov. 6, 2026 in Healthcare
Bioliberty, a company developing soft-robotic rehabilitation technology for upper-extremity recovery, has raised a €2.95 million ($3.3 million) Series A extension. TGH Ventures, Ballad Ventures, Whiterock and 25m Health joined as new institutional backers.
Why it matters
The extension brings Bioliberty's total funding to €12.07 million ($13.5 million), supporting expansion of its technology beyond inpatient settings. The round reflects continued investor interest in rehabilitation tools that connect hospital care with home recovery.
Bioliberty's total funding now stands at €12.07 million ($13.5 million), up from €9.12 million ($10.2 million) raised in its earlier pre-Series A and Series A rounds. The company has not disclosed valuation or the specific amount contributed by each new backer.
The players
Bioliberty
An Edinburgh and Boston-based company developing soft-robotic rehabilitation technology for upper-extremity recovery, founded in 2020.
TGH Ventures
The investment arm of Tampa General Hospital, which joined Bioliberty's funding round as a new institutional backer.
The details
Bioliberty develops soft-robotic rehabilitation technology designed to aid upper-extremity recovery, with therapy sessions that can begin in under five minutes. The technology was co-developed with inpatient rehabilitation facilities and is FDA-listed in the United States through its Lifehub and Lifeglov products.
Timeline
Bioliberty was founded in 2020 by four Northern Ireland co-founders.
A clinical study with the Mount Sinai health system was conducted in 2024.
Bioliberty launched commercially in the United States in 2025.
Healthcare Landscape
Bioliberty's commercial rollout in the United States after FDA listing of its Lifehub and Lifeglov devices places it among rehabilitation technology firms moving from clinical study into hospital-based recovery programs. The round signals that investors are backing tools that bridge inpatient rehabilitation and at-home care.
Patients recovering from upper-limb injuries may gain access to therapy that begins in under five minutes, with the company expanding toward home-based use. Clinicians and rehabilitation facilities gain another option for connecting recovery data across care settings.
The takeaway
Investment in rehabilitation technology is increasingly directed at tools that carry patient recovery beyond the hospital, so readers following medical devices should watch for home-use and data-connected products as they reach market.
Further reading
Explore more Healthcare business coverage to see how investment is reshaping medical technology.
Source note: This article includes information reported by EU-Startups.
